Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 620-625

  Pierre, Falardeau ^a   Pierre, Champagne ^a   Patrick, Poyet ^a   Claude, Hariton ^a   Éric, Dupont ^a  

^a Æterna Laboratories Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; GELATINASE A; GELATINASE B; MATRIGEL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL PERMEABILITY; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONKEY; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; TUMOR VOLUME;

EID: 0035207897     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28598     Document Type: Review

References (42)

1. Mechanisms of bone lesions in multiple myeloma and lymphoma
2. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
3. Bone marrow angiogenesis and progression in multiple myeloma
4. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44
5. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
6. Prognostic factors in multiple myeloma
7. Etiology of multiple myeloma: What's new
8. The thin red line: Angiogenesis in normal and malignant hematopoiesis
9. Increased vascularization in myeloma
10. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
11. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma
12. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
13. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
14. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells
15. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
16. Mechanisms of bone lesions in multiple myeloma
17. Cell biology of the osteoclast
18. Antitumor activity of thalidomide in refractory multiple myeloma
19. Thalidomide is an inhibitor of angiogenesis
20. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
21. Inhibition of tumor angiogenesis mediated by cartilage
22. Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?
23. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
24. Identification of an inhibitor of neovascularization from cartilage
25. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
26. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis
27. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium
28. Chondrocytes inhibit endothelial sprout formation in vitro: Evidence for involvement of a transforming growth factor-beta
29. Cartilagederived anti-tumor factor (CATF): Partial purification and correlation of inhibitory activity against tumor growth with anti-angiogenic activity
30. A cartilage-derived inhibitor of neovascularization and metalloproteinases
31. Metastatin: A hyaluronan-binding complex from cartilage that inhibits tumor growth
32. Shark cartilage contains inhibitors of tumor angiogenesis
33. Inhibition of new blood vessel formation in mice by systemic administration of human rib cartilage extract
34. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer
35. Matrix proteinase inhibition by Æ- 941, a multifunctional antiangiogenic compound
36. Cartilage as a source of natural inhibitors of angiogenesis